Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells

2018134 citationsJournal Articlegold Open Access

Authors

Anandani Nellan · Morgan Adams Foundation

Christopher Rota · Harvard University

Robbie G. Majzner · Stanford University

Cynthia M. Lester-McCully · National Cancer Institute

Andrea M. Griesinger · Children's Hospital Colorado

Jean M. Mulcahy Levy · Morgan Adams Foundation

Nicholas K. Foreman

Abstract

HER2-BBz-CAR T cells show excellent pre-clinical efficacy in vitro and in mouse medulloblastoma models, and their intraventricular delivery is feasible and safe in NHPs. A clinical trial of HER2-BBz-CAR T cells directly delivered into cerebrospinal fluid should be designed for patients with relapsed medulloblastoma.

Topics & Keywords

CAR-T cell therapy research Advanced Machining and Optimization Techniques Integrated Circuits and Semiconductor Failure Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal for ImmunoTherapy of Cancer

Volume 6, Issue 1, pp. 30-30

DOI: 10.1186/s40425-018-0340-z

Field-Weighted Citation Impact: 5.58